{"id":"ckd-314-soc","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CKD-314 activates peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor that regulates genes involved in glucose homeostasis and insulin signaling. By enhancing insulin sensitivity in adipose tissue and skeletal muscle, it improves glycemic control. The '+SOC' designation indicates it is being evaluated as an add-on therapy to standard of care treatments in type 2 diabetes.","oneSentence":"CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:10.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (as add-on to standard of care)"}]},"trialDetails":[{"nctId":"NCT04871646","phase":"PHASE3","title":"Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-06-30","conditions":"COVID-19 Pneumonia","enrollment":586}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKD-314+SOC","genericName":"CKD-314+SOC","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-314 is a selective PPAR-gamma agonist that enhances insulin sensitivity and glucose metabolism when combined with standard of care. Used for Type 2 diabetes mellitus (as add-on to standard of care).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}